502 is the total number of securities Rock Springs Capital Management LP has owned. The longest Rock Springs Capital Management LP has owned a single stock is 40 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
ISRG | INTUITIVE SURGICAL INC | 40 | 40 | 1.06% | 2.19% | 3.44% | Q4 2013 | Q3 2023 | 40 |
NBIX | NEUROCRINE BIOSCIENCES... | 39 | 39 | 0.76% | 2.31% | 4.83% | Q1 2014 | Q3 2023 | 39 |
PCRX | PACIRA PHARMACEUTICALS... | 35 | 4 | 0.35% | 1.46% | 2.63% | Q4 2013 | Q3 2023 | 39 |
RARE | ULTRAGENYX PHARMACEUTI... | 39 | 39 | 0.34% | 0.98% | 1.90% | Q1 2014 | Q3 2023 | 39 |
ACHC | ACADIA HEALTHCARE COMP... | 38 | 38 | 0.57% | 1.84% | 4.37% | Q2 2014 | Q3 2023 | 38 |
ASND | ASCENDIS PHARMA A/S | 35 | 35 | 0.06% | 0.75% | 1.34% | Q1 2015 | Q3 2023 | 35 |
NVTA | INVITAE CORP | 35 | 35 | 0.01% | 0.69% | 1.85% | Q1 2015 | Q3 2023 | 35 |
BMRN | BIOMARIN PHARMACEUTICA... | 35 | 35 | 0.32% | 0.59% | 1.33% | Q1 2015 | Q3 2023 | 35 |
MGNX | MACROGENICS INC | 35 | 35 | 0.05% | 0.23% | 0.51% | Q1 2015 | Q3 2023 | 35 |
COLL | COLLEGIUM PHARMACEUTIC... | 34 | 34 | 0.30% | 0.93% | 2.10% | Q2 2015 | Q3 2023 | 34 |
FOLD | AMICUS THERAPEUTICS INC | 34 | 34 | 0.19% | 0.38% | 0.64% | Q2 2015 | Q3 2023 | 34 |
ADAP | ADAPTIMMUNE THERAPEUTI... | 34 | 34 | 0.03% | 0.28% | 1.21% | Q2 2015 | Q3 2023 | 34 |
PEN | PENUMBRA INC | 33 | 33 | 0.59% | 1.39% | 3.26% | Q3 2015 | Q3 2023 | 33 |
DVAX | DYNAVAX TECHNOLOGIES CORP | 33 | 33 | 0.04% | 0.29% | 0.72% | Q3 2015 | Q3 2023 | 33 |
CGEN | COMPUGEN LTD | 33 | 33 | 0.02% | 0.20% | 0.47% | Q3 2015 | Q3 2023 | 33 |
EW | EDWARDS LIFESCIENCES CORP | 31 | 1 | 0.56% | 1.18% | 1.77% | Q4 2013 | Q3 2023 | 32 |
SRPT | SAREPTA THERAPEUTICS INC | 32 | 32 | 0.18% | 0.98% | 1.82% | Q4 2015 | Q3 2023 | 32 |
ACRS | ACLARIS THERAPEUTICS INC | 32 | 32 | 0.07% | 0.91% | 2.00% | Q4 2015 | Q3 2023 | 32 |
PRTA | PROTHENA CORP PLC | 17 | 15 | 0.22% | 0.78% | 1.28% | Q1 2014 | Q3 2023 | 32 |
EPZM | EPIZYME INC | 32 | 32 | 0.21% | 0.64% | 1.59% | Q3 2014 | Q2 2022 | 32 |
PRTK | PARATEK PHARMACEUTICAL... | 31 | 31 | 0.04% | 0.23% | 0.73% | Q4 2015 | Q2 2023 | 31 |
UNH | UNITEDHEALTH GROUP INC | 28 | 2 | 1.56% | 3.66% | 7.09% | Q4 2013 | Q3 2023 | 30 |
TBPH | THERAVANCE BIOPHARMA INC | 30 | 30 | 0.11% | 0.65% | 1.36% | Q2 2014 | Q3 2021 | 30 |
HCA | HCA HOLDINGS INC | 17 | 12 | 0.81% | 2.16% | 3.50% | Q4 2013 | Q1 2022 | 29 |
EXAS | EXACT SCIENCES CORP | 29 | 29 | 0.40% | 1.11% | 2.11% | Q3 2016 | Q3 2023 | 29 |
MDGL | MADRIGAL PHARMACEUTICA... | 29 | 29 | 0.05% | 1.00% | 3.68% | Q3 2016 | Q3 2023 | 29 |
INCY | INCYTE CORP | 29 | 29 | 0.55% | 0.88% | 1.30% | Q4 2013 | Q4 2020 | 29 |
FPRX | FIVE PRIME THERAPEUTIC... | 29 | 29 | 0.03% | 0.37% | 2.19% | Q1 2014 | Q1 2021 | 29 |
AGLE | AEGLEA BIOTHERAPEUTICS... | 29 | 29 | 0.02% | 0.18% | 0.40% | Q2 2016 | Q2 2023 | 29 |
VRTX | VERTEX PHARMACEUTICALS... | 28 | 28 | 0.06% | 0.90% | 1.59% | Q4 2013 | Q3 2020 | 28 |
XENT | INTERSECT ENT INC | 28 | 28 | 0.19% | 0.47% | 0.70% | Q2 2015 | Q1 2022 | 28 |
BIIB | BIOGEN INC | 21 | 6 | 0.52% | 1.44% | 5.30% | Q4 2013 | Q2 2021 | 27 |
FGEN | FIBROGEN INC | 27 | 27 | 0.16% | 0.45% | 0.81% | Q4 2014 | Q2 2021 | 27 |
ALXN | ALEXION PHARMACEUTICAL... | 23 | 3 | 0.56% | 2.07% | 3.81% | Q4 2013 | Q4 2020 | 26 |
IDXX | IDEXX LABS INC | 23 | 3 | 0.51% | 1.53% | 3.01% | Q2 2015 | Q3 2023 | 26 |
ALGN | ALIGN TECHNOLOGY INC | 26 | 26 | 0.17% | 1.46% | 3.04% | Q2 2017 | Q3 2023 | 26 |
ALNY | ALNYLAM PHARMACEUTICAL... | 26 | 26 | 0.42% | 1.12% | 1.90% | Q2 2017 | Q3 2023 | 26 |
MRSN | MERSANA THERAPEUTICS INC | 26 | 26 | 0.09% | 0.59% | 1.21% | Q2 2017 | Q3 2023 | 26 |
NVCR | NOVOCURE LTD | 20 | 6 | 0.05% | 0.34% | 0.77% | Q4 2015 | Q2 2023 | 26 |
RIGL | RIGEL PHARMACEUTICALS INC | 26 | 26 | 0.12% | 0.33% | 0.48% | Q4 2015 | Q1 2022 | 26 |
HUM | HUMANA INC | 16 | 2 | 1.22% | 2.95% | 5.81% | Q4 2013 | Q3 2023 | 25 |
BPMC | BLUEPRINT MEDICINES CORP | 25 | 25 | 0.28% | 1.54% | 3.61% | Q3 2017 | Q3 2023 | 25 |
GWPH | GW PHARMACEUTICALS PLC | 20 | 1 | 0.11% | 1.54% | 4.55% | Q1 2014 | Q4 2020 | 25 |
IRTC | IRHYTHM TECHNOLOGIES INC | 25 | 25 | 0.55% | 1.42% | 3.78% | Q3 2017 | Q3 2023 | 25 |
ZLAB | ZAI LAB LTD | 25 | 25 | 0.25% | 1.18% | 3.55% | Q3 2017 | Q3 2023 | 25 |
MDCO | MEDICINES CO | 25 | 25 | 0.45% | 1.12% | 1.98% | Q4 2013 | Q4 2019 | 25 |
GLPG | GALAPAGOS NV | 25 | 25 | 0.22% | 0.79% | 1.42% | Q2 2015 | Q2 2021 | 25 |
ARDX | ARDELYX INC | 25 | 25 | 0.17% | 0.77% | 1.90% | Q2 2015 | Q2 2021 | 25 |
CHRS | COHERUS BIOSCIENCES INC | 25 | 25 | 0.25% | 0.69% | 1.52% | Q4 2014 | Q4 2020 | 25 |
WCG | WELLCARE HEALTH PLANS INC | 17 | 7 | 0.37% | 1.79% | 4.34% | Q4 2013 | Q4 2019 | 24 |
CELG | CELGENE CORP | 24 | 24 | 0.56% | 1.72% | 3.74% | Q4 2013 | Q3 2019 | 24 |
MRTX | MIRATI THERAPEUTICS INC | 24 | 24 | 0.15% | 0.99% | 1.74% | Q4 2017 | Q3 2023 | 24 |
RTIX | RTI SURGICAL INC | 24 | 24 | 0.17% | 0.58% | 1.38% | Q1 2014 | Q4 2019 | 24 |
RYTM | RHYTHM PHARMACEUTICALS... | 24 | 24 | 0.06% | 0.38% | 1.23% | Q4 2017 | Q3 2023 | 24 |
ANAB | ANAPTYSBIO INC | 24 | 24 | 0.07% | 0.34% | 0.65% | Q3 2017 | Q2 2023 | 24 |
SPRO | SPERO THERAPEUTICS INC | 24 | 24 | 0.00% | 0.21% | 0.51% | Q4 2017 | Q3 2023 | 24 |
CHMA | CHIASMA INC | 24 | 24 | 0.03% | 0.19% | 0.84% | Q3 2015 | Q2 2021 | 24 |
RDUS | RADIUS HEALTH INC | 23 | 23 | 0.23% | 1.57% | 3.15% | Q1 2015 | Q3 2020 | 23 |
AMRN | AMARIN CORP PLC | 23 | 23 | 0.34% | 1.26% | 3.62% | Q3 2016 | Q1 2022 | 23 |
RTRX | RETROPHIN INC | 23 | 23 | 0.26% | 0.64% | 1.63% | Q1 2015 | Q3 2020 | 23 |
PBYI | PUMA BIOTECHNOLOGY INC | 21 | 2 | 0.06% | 0.57% | 1.82% | Q4 2013 | Q3 2019 | 23 |
ASMB | ASSEMBLY BIOSCIENCES INC | 23 | 23 | 0.16% | 0.52% | 0.97% | Q1 2015 | Q3 2020 | 23 |
THERAVANCE BIOPHARMA INC | 23 | 23 | 0.03% | 0.06% | 0.12% | Q4 2016 | Q2 2022 | 23 | |
ARGX | ARGENX SE | 22 | 22 | 0.41% | 1.97% | 3.86% | Q2 2018 | Q3 2023 | 22 |
TMO | THERMO FISHER SCIENTIF... | 12 | 4 | 0.20% | 1.22% | 2.97% | Q4 2013 | Q1 2020 | 22 |
BGNE | BEIGENE LTD | 22 | 22 | 0.44% | 1.06% | 1.59% | Q1 2016 | Q2 2021 | 22 |
BAX | BAXTER INTL INC | 16 | 6 | 0.26% | 1.06% | 2.16% | Q2 2017 | Q4 2022 | 22 |
WST | WEST PHARMACEUTICAL SV... | 22 | 22 | 0.17% | 0.76% | 2.03% | Q2 2018 | Q3 2023 | 22 |
NVAX | NOVAVAX INC | 22 | 22 | 0.04% | 0.29% | 0.58% | Q4 2013 | Q1 2019 | 22 |
NEUROCRINE BIOSCIENCES... | 22 | 22 | 0.03% | 0.04% | 0.06% | Q2 2018 | Q3 2023 | 22 | |
TSRO | TESARO INC | 21 | 21 | 0.59% | 1.91% | 5.52% | Q4 2013 | Q4 2018 | 21 |
ACHN | ACHILLION PHARMACEUTIC... | 21 | 21 | 0.18% | 0.49% | 0.90% | Q4 2014 | Q4 2019 | 21 |
DERM | DERMIRA INC | 21 | 21 | 0.06% | 0.43% | 0.77% | Q4 2014 | Q4 2019 | 21 |
BLUE | BLUEBIRD BIO INC | 21 | 21 | 0.06% | 0.22% | 0.55% | Q4 2014 | Q4 2019 | 21 |
FRPT | FRESHPET INC | 20 | 20 | 0.36% | 1.07% | 1.76% | Q4 2018 | Q3 2023 | 20 |
JAZZ | JAZZ PHARMACEUTICALS PLC | 16 | 2 | 0.21% | 0.68% | 1.07% | Q4 2013 | Q4 2020 | 20 |
INSM | INSMED INC | 20 | 20 | 0.36% | 0.63% | 0.95% | Q1 2015 | Q4 2019 | 20 |
GBT | GLOBAL BLOOD THERAPEUT... | 20 | 20 | 0.09% | 0.32% | 0.67% | Q3 2015 | Q2 2020 | 20 |
RADIUS HEALTH INC | 20 | 20 | 0.03% | 0.04% | 0.07% | Q3 2017 | Q2 2022 | 20 | |
GILD | GILEAD SCIENCES INC | 19 | 19 | 1.00% | 2.64% | 7.65% | Q4 2013 | Q2 2018 | 19 |
ONCE | SPARK THERAPEUTICS INC | 19 | 19 | 0.24% | 1.77% | 2.46% | Q1 2015 | Q3 2019 | 19 |
AGIO | AGIOS PHARMACEUTICALS INC | 19 | 19 | 0.31% | 1.70% | 2.87% | Q1 2019 | Q3 2023 | 19 |
AMGN | AMGEN INC | 14 | 1 | 0.49% | 1.61% | 3.27% | Q4 2013 | Q3 2023 | 19 |
PRAH | PRA HEALTH SCIENCES INC | 19 | 19 | 0.76% | 1.11% | 1.97% | Q4 2014 | Q2 2019 | 19 |
NVRO | NEVRO CORP | 19 | 19 | 0.08% | 1.08% | 1.74% | Q1 2019 | Q3 2023 | 19 |
GH | GUARDANT HEALTH INC | 19 | 19 | 0.11% | 0.42% | 0.67% | Q4 2018 | Q2 2023 | 19 |
PODD | INSULET CORP | 18 | 18 | 1.06% | 2.44% | 4.08% | Q2 2019 | Q3 2023 | 18 |
KRTX | KARUNA THERAPEUTICS INC | 18 | 18 | 0.23% | 1.20% | 2.55% | Q2 2019 | Q3 2023 | 18 |
AKRO | AKERO THERAPEUTICS INC | 18 | 18 | 0.16% | 0.62% | 1.92% | Q2 2019 | Q3 2023 | 18 |
GMDA | GAMIDA CELL LTD | 18 | 18 | 0.00% | 0.17% | 0.37% | Q2 2019 | Q3 2023 | 18 |
INFI | INFINITY PHARMACEUTICA... | 18 | 18 | 0.02% | 0.17% | 0.47% | Q4 2013 | Q1 2018 | 18 |
AET | AETNA INC NEW | 16 | 1 | 1.33% | 2.43% | 3.98% | Q4 2013 | Q1 2018 | 17 |
EHC | ENCOMPASS HEALTH CORP | 17 | 17 | 0.76% | 1.36% | 2.16% | Q1 2018 | Q1 2022 | 17 |
PHR | PHREESIA INC | 17 | 17 | 0.35% | 0.82% | 1.26% | Q3 2019 | Q3 2023 | 17 |
MIRM | MIRUM PHARMACEUTICALS INC | 17 | 17 | 0.32% | 0.81% | 1.54% | Q3 2019 | Q3 2023 | 17 |
ARVN | ARVINAS INC | 17 | 17 | 0.08% | 0.50% | 1.34% | Q3 2018 | Q3 2022 | 17 |
HCAT | HEALTH CATALYST INC | 17 | 17 | 0.08% | 0.47% | 0.89% | Q3 2019 | Q3 2023 | 17 |
CO | CHINA CORD BLOOD CORP | 17 | 17 | 0.28% | 0.45% | 0.74% | Q4 2013 | Q4 2017 | 17 |
MYOV | MYOVANT SCIENCES LTD | 17 | 17 | 0.08% | 0.21% | 0.33% | Q4 2016 | Q4 2020 | 17 |
TFX | TELEFLEX INCORPORATED | 16 | 16 | 0.96% | 1.28% | 1.76% | Q4 2017 | Q3 2021 | 16 |
NVAX | NOVAVAX INC | 14 | 2 | 0.03% | 0.86% | 1.98% | Q2 2019 | Q3 2023 | 16 |
PTLA | PORTOLA PHARMACEUTICAL... | 13 | 3 | 0.28% | 0.64% | 1.17% | Q4 2015 | Q2 2020 | 16 |
CLVS | CLOVIS ONCOLOGY INC | 16 | 16 | 0.04% | 0.41% | 1.10% | Q4 2015 | Q3 2019 | 16 |
CRVS | CORVUS PHARMACEUTICALS... | 16 | 16 | 0.03% | 0.26% | 0.56% | Q1 2016 | Q4 2019 | 16 |
APLT | APPLIED THERAPEUTICS INC | 16 | 16 | 0.01% | 0.26% | 1.14% | Q4 2019 | Q3 2023 | 16 |
PHAS | PHASEBIO PHARMACEUTICA... | 16 | 16 | 0.01% | 0.18% | 0.68% | Q4 2018 | Q3 2022 | 16 |
PACIRA PHARMACEUTICALS... | 16 | 16 | 0.02% | 0.03% | 0.05% | Q1 2018 | Q4 2021 | 16 | |
CI | CIGNA CORPORATION | 15 | 15 | 1.05% | 1.78% | 2.96% | Q2 2014 | Q4 2017 | 15 |
BSX | BOSTON SCIENTIFIC CORP | 13 | 2 | 0.22% | 1.11% | 1.72% | Q2 2018 | Q3 2023 | 15 |
XENE | XENON PHARMACEUTICALS INC | 15 | 15 | 0.14% | 0.59% | 1.12% | Q1 2020 | Q3 2023 | 15 |
CVET | COVETRUS INC | 15 | 15 | 0.01% | 0.57% | 1.01% | Q1 2019 | Q3 2022 | 15 |
ALDR | ALDER BIOPHARMACEUTICA... | 15 | 15 | 0.10% | 0.56% | 0.98% | Q1 2016 | Q3 2019 | 15 |
OBSV | OBSEVA SA | 15 | 15 | 0.09% | 0.41% | 0.73% | Q1 2017 | Q3 2020 | 15 |
MEDICINES CO | 15 | 15 | 0.12% | 0.19% | 0.28% | Q1 2016 | Q3 2019 | 15 | |
TRAVERE THERAPEUTICS INC | 15 | 15 | 0.06% | 0.08% | 0.11% | Q1 2020 | Q3 2023 | 15 | |
ABBV | ABBVIE INC | 9 | 2 | 0.39% | 2.77% | 4.69% | Q4 2013 | Q3 2019 | 14 |
VRX | VALEANT PHARMACEUTICAL... | 14 | 14 | 0.04% | 1.13% | 3.07% | Q4 2013 | Q1 2017 | 14 |
WMGI | WRIGHT MED GROUP N V | 14 | 14 | 0.68% | 0.94% | 1.28% | Q4 2015 | Q1 2019 | 14 |
SWAV | SHOCKWAVE MED INC | 14 | 14 | 0.26% | 0.80% | 1.42% | Q2 2020 | Q3 2023 | 14 |
BOLD | AUDENTES THERAPEUTICS INC | 14 | 14 | 0.46% | 0.62% | 0.79% | Q3 2016 | Q4 2019 | 14 |
CNMD | CONMED CORP | 14 | 14 | 0.18% | 0.47% | 0.76% | Q1 2020 | Q2 2023 | 14 |
REGN | REGENERON PHARMACEUTICALS | 12 | 2 | 0.33% | 0.42% | 0.52% | Q1 2014 | Q3 2017 | 14 |
LEGN | LEGEND BIOTECH CORP | 14 | 14 | 0.18% | 0.42% | 0.82% | Q2 2020 | Q3 2023 | 14 |
ICPT | INTERCEPT PHARMACEUTIC... | 11 | 3 | 0.11% | 0.41% | 0.99% | Q4 2013 | Q4 2019 | 14 |
TNDM | TANDEM DIABETES CARE INC | 14 | 14 | 0.02% | 0.34% | 0.58% | Q2 2014 | Q3 2017 | 14 |
MCRB | SERES THERAPEUTICS INC | 14 | 14 | 0.06% | 0.28% | 0.65% | Q2 2015 | Q3 2018 | 14 |
GOSSAMER BIO INC | 14 | 14 | 0.06% | 0.24% | 0.43% | Q2 2020 | Q3 2023 | 14 | |
PTI | PROTEOSTASIS THERAPEUT... | 10 | 4 | 0.01% | 0.17% | 0.44% | Q1 2016 | Q3 2019 | 14 |
CDTX | CIDARA THERAPEUTICS INC | 14 | 14 | 0.05% | 0.17% | 0.32% | Q2 2015 | Q3 2018 | 14 |
NABRIVA THERAPEUTICS PLC | 14 | 14 | 0.01% | 0.13% | 0.28% | Q2 2017 | Q3 2020 | 14 | |
SCYX | SCYNEXIS INC | 14 | 14 | 0.04% | 0.13% | 0.30% | Q2 2015 | Q3 2018 | 14 |
NEVRO CORP | 14 | 14 | 0.01% | 0.01% | 0.02% | Q2 2020 | Q3 2023 | 14 | |
MCK | MCKESSON CORP | 12 | 1 | 0.03% | 2.25% | 3.97% | Q4 2013 | Q2 2018 | 13 |
HZNP | HORIZON THERAPEUTICS P... | 13 | 13 | 0.79% | 1.46% | 2.03% | Q3 2020 | Q3 2023 | 13 |
BMY | BRISTOL MYERS SQUIBB CO | 9 | 1 | 0.14% | 1.22% | 3.43% | Q4 2013 | Q4 2019 | 13 |
KYMR | KYMERA THERAPEUTICS INC | 13 | 13 | 0.44% | 0.73% | 1.09% | Q3 2020 | Q3 2023 | 13 |
ALLK | ALLAKOS INC | 13 | 13 | 0.43% | 0.69% | 1.01% | Q3 2018 | Q3 2021 | 13 |
ACCD | ACCOLADE INC | 13 | 13 | 0.32% | 0.65% | 0.90% | Q3 2020 | Q3 2023 | 13 |
RARX | RA PHARMACEUTICALS INC | 13 | 13 | 0.14% | 0.62% | 1.11% | Q4 2016 | Q4 2019 | 13 |
JUNO | JUNO THERAPEUTICS INC | 13 | 13 | 0.25% | 0.54% | 0.88% | Q4 2014 | Q4 2017 | 13 |
PRGO | PERRIGO CO PLC | 7 | 6 | 0.04% | 0.45% | 1.02% | Q1 2014 | Q2 2017 | 13 |
NVDQ | NOVADAQ TECHNOLOGIES INC | 13 | 13 | 0.09% | 0.44% | 0.73% | Q2 2014 | Q2 2017 | 13 |
BHVN | BIOHAVEN PHARMACTL HLD... | 13 | 13 | 0.28% | 0.43% | 0.60% | Q2 2017 | Q2 2020 | 13 |
KITE | KITE PHARMA INC | 13 | 13 | 0.24% | 0.40% | 0.77% | Q3 2014 | Q3 2017 | 13 |
ODT | ODONATE THERAPEUTICS INC | 13 | 13 | 0.15% | 0.38% | 0.57% | Q4 2017 | Q4 2020 | 13 |
ZGNX | ZOGENIX INC | 13 | 13 | 0.16% | 0.37% | 0.50% | Q3 2017 | Q3 2020 | 13 |
CRME | CARDIOME PHARMA CORP | 13 | 13 | 0.08% | 0.35% | 0.82% | Q1 2015 | Q1 2018 | 13 |
TBIO | TRANSLATE BIO INC | 13 | 13 | 0.22% | 0.34% | 0.49% | Q2 2018 | Q2 2021 | 13 |
BCRX | BIOCRYST PHARMACEUTICA... | 7 | 6 | 0.06% | 0.32% | 0.56% | Q3 2017 | Q3 2023 | 13 |
RLAY | RELAY THERAPEUTICS INC | 13 | 13 | 0.15% | 0.31% | 0.45% | Q3 2020 | Q3 2023 | 13 |
INZY | INOZYME PHARMA INC | 13 | 13 | 0.08% | 0.31% | 0.59% | Q3 2020 | Q3 2023 | 13 |
ITCI | INTRA CELLULAR THERAPI... | 13 | 13 | 0.12% | 0.28% | 0.73% | Q3 2015 | Q3 2018 | 13 |
EXEL | EXELIXIS INC | 10 | 3 | 0.10% | 0.26% | 0.58% | Q4 2013 | Q4 2018 | 13 |
NKTX | NKARTA INC | 13 | 13 | 0.01% | 0.23% | 0.70% | Q3 2020 | Q3 2023 | 13 |
AUPH | AURINIA PHARMACEUTICAL... | 13 | 13 | 0.05% | 0.20% | 0.29% | Q3 2020 | Q3 2023 | 13 |
CERU | CERULEAN PHARMA INC | 13 | 13 | 0.01% | 0.14% | 0.46% | Q2 2014 | Q2 2017 | 13 |
BCEL | ATRECA INC | 13 | 13 | 0.00% | 0.06% | 0.16% | Q3 2020 | Q3 2023 | 13 |
AGN | ALLERGAN PLC | 9 | 3 | 0.11% | 2.15% | 3.84% | Q2 2015 | Q3 2018 | 12 |
SGEN | SEAGEN INC | 12 | 12 | 0.76% | 1.24% | 2.27% | Q4 2020 | Q3 2023 | 12 |
CERE | CEREVEL THERAPEUTICS H... | 12 | 12 | 0.30% | 1.24% | 1.90% | Q4 2020 | Q3 2023 | 12 |
HLS | HEALTHSOUTH CORP | 12 | 12 | 0.51% | 0.72% | 1.05% | Q1 2015 | Q4 2017 | 12 |
ABCM | ABCAM PLC | 12 | 12 | 0.41% | 0.69% | 1.40% | Q4 2020 | Q3 2023 | 12 |
ATHN | ATHENAHEALTH INC | 8 | 4 | 0.32% | 0.65% | 1.40% | Q4 2013 | Q1 2017 | 12 |
TVTX | TRAVERE THERAPEUTICS INC | 12 | 12 | 0.43% | 0.61% | 0.80% | Q4 2020 | Q3 2023 | 12 |
LUNG | PULMONX CORP | 12 | 12 | 0.13% | 0.38% | 0.73% | Q4 2020 | Q3 2023 | 12 |
SPRB | SPRUCE BIOSCIENCES INC | 12 | 12 | 0.04% | 0.24% | 0.84% | Q4 2020 | Q3 2023 | 12 |
INSMED INC | 12 | 12 | 0.14% | 0.19% | 0.23% | Q1 2018 | Q4 2020 | 12 | |
CO | GLOBAL CORD BLOOD CORP... | 12 | 12 | 0.06% | 0.19% | 0.38% | Q1 2018 | Q4 2020 | 12 |
KNTE | KINNATE BIOPHARMA INC | 12 | 12 | 0.02% | 0.15% | 0.27% | Q4 2020 | Q3 2023 | 12 |
IMCR | IMMUNOCORE HLDGS PLC | 11 | 11 | 1.85% | 3.04% | 4.56% | Q1 2021 | Q3 2023 | 11 |
EVH | EVOLENT HEALTH INC | 11 | 11 | 0.64% | 2.03% | 3.03% | Q1 2021 | Q3 2023 | 11 |
EVHC | ENVISION HEALTHCARE HL... | 11 | 11 | 0.41% | 1.11% | 2.04% | Q1 2014 | Q3 2016 | 11 |
DXCM | DEXCOM INC | 11 | 11 | 0.12% | 0.98% | 1.50% | Q1 2021 | Q3 2023 | 11 |
HTWR | HEARTWARE INTL INC | 11 | 11 | 0.51% | 0.95% | 1.33% | Q4 2013 | Q2 2016 | 11 |
ACAD | ACADIA PHARMACEUTICALS... | 8 | 1 | 0.24% | 0.89% | 1.83% | Q4 2013 | Q2 2021 | 11 |
IMMU | IMMUNOMEDICS INC | 11 | 11 | 0.28% | 0.88% | 3.42% | Q1 2018 | Q3 2020 | 11 |
SGEN | SEATTLE GENETICS INC | 8 | 3 | 0.26% | 0.72% | 1.24% | Q2 2017 | Q3 2020 | 11 |
OREX | OREXIGEN THERAPEUTICS INC | 11 | 11 | 0.05% | 0.70% | 1.24% | Q4 2013 | Q2 2016 | 11 |
TXMD | THERAPEUTICSMD INC | 11 | 11 | 0.24% | 0.60% | 0.99% | Q3 2015 | Q1 2018 | 11 |
OLK | OLINK HLDG AB | 11 | 11 | 0.22% | 0.52% | 0.89% | Q1 2021 | Q3 2023 | 11 |
ADRO | ADURO BIOTECH INC | 11 | 11 | 0.14% | 0.42% | 0.88% | Q2 2015 | Q4 2017 | 11 |
AIMT | AIMMUNE THERAPEUTICS INC | 11 | 11 | 0.22% | 0.34% | 0.50% | Q3 2015 | Q1 2018 | 11 |
MNTA | MOMENTA PHARMACEUTICAL... | 11 | 11 | 0.18% | 0.32% | 0.53% | Q1 2018 | Q3 2020 | 11 |
AGNPRA | ALLERGAN PLC | 11 | 11 | 0.13% | 0.28% | 0.39% | Q2 2015 | Q4 2017 | 11 |
KDNY | CHINOOK THERAPEUTICS INC | 11 | 11 | 0.18% | 0.26% | 0.36% | Q4 2020 | Q2 2023 | 11 |
CBAY | CYMABAY THERAPEUTICS INC | 9 | 2 | 0.12% | 0.24% | 0.37% | Q3 2014 | Q3 2019 | 11 |
TTPH | TETRAPHASE PHARMACEUTI... | 9 | 2 | 0.14% | 0.23% | 0.37% | Q1 2015 | Q4 2017 | 11 |
MEDICINES CO | 11 | 11 | 0.16% | 0.21% | 0.28% | Q2 2017 | Q4 2019 | 11 | |
MREO | MEREO BIOPHARMA GROUP PLC | 11 | 11 | 0.10% | 0.21% | 0.33% | Q1 2021 | Q3 2023 | 11 |
LIFE | ATYR PHARMA INC | 11 | 11 | 0.07% | 0.18% | 0.55% | Q2 2015 | Q4 2017 | 11 |
DBVT | DBV TECHNOLOGIES S A | 11 | 11 | 0.07% | 0.13% | 0.20% | Q3 2015 | Q1 2018 | 11 |
DSGN | DESIGN THERAPEUTICS INC | 11 | 11 | 0.03% | 0.13% | 0.21% | Q1 2021 | Q3 2023 | 11 |
EPIX | ESSA PHARMA INC | 11 | 11 | 0.02% | 0.11% | 0.32% | Q1 2021 | Q3 2023 | 11 |
FATE | FATE THERAPEUTICS INC | 11 | 11 | 0.03% | 0.09% | 0.15% | Q1 2021 | Q3 2023 | 11 |
NUVBWS | NUVATION BIO INC | 11 | 11 | 0.00% | 0.00% | 0.01% | Q1 2021 | Q3 2023 | 11 |
AGL | AGILON HEALTH INC | 10 | 10 | 3.06% | 4.35% | 5.61% | Q2 2021 | Q3 2023 | 10 |
MOH | MOLINA HEALTHCARE INC | 10 | 10 | 0.92% | 1.62% | 2.93% | Q2 2017 | Q3 2019 | 10 |
XLV | SELECT SECTOR SPDR TR | 6 | 2 | 0.62% | 1.59% | 7.33% | Q4 2013 | Q3 2023 | 10 |
COO | COOPER COS INC | 10 | 10 | 0.45% | 1.03% | 1.92% | Q4 2013 | Q1 2016 | 10 |
A | AGILENT TECHNOLOGIES INC | 6 | 4 | 0.26% | 0.90% | 2.72% | Q4 2013 | Q2 2019 | 10 |
CLSD | CLEARSIDE BIOMEDICAL INC | 10 | 10 | 0.22% | 0.52% | 1.33% | Q2 2016 | Q3 2018 | 10 |
LFST | LIFESTANCE HEALTH GROU... | 10 | 10 | 0.32% | 0.51% | 0.83% | Q2 2021 | Q3 2023 | 10 |
MRUS | MERUS N V | 8 | 2 | 0.14% | 0.35% | 0.56% | Q2 2016 | Q3 2023 | 10 |
HRTX | HERON THERAPEUTICS INC | 7 | 3 | 0.02% | 0.35% | 0.78% | Q3 2014 | Q2 2019 | 10 |
HQY | HEALTHEQUITY INC | 5 | 5 | 0.11% | 0.34% | 0.64% | Q4 2016 | Q4 2020 | 10 |
FIXX | HOMOLOGY MEDICINES INC | 10 | 10 | 0.15% | 0.34% | 0.48% | Q1 2018 | Q2 2020 | 10 |
BMEA | BIOMEA FUSION INC | 10 | 10 | 0.07% | 0.32% | 0.96% | Q2 2021 | Q3 2023 | 10 |
EDAP | EDAP TMS S A | 10 | 10 | 0.10% | 0.19% | 0.27% | Q2 2021 | Q3 2023 | 10 |
RPHM | RENEO PHARMACEUTICALS INC | 10 | 10 | 0.06% | 0.15% | 0.23% | Q2 2021 | Q3 2023 | 10 |
TPST | TEMPEST THERAPEUTICS INC | 10 | 10 | 0.00% | 0.05% | 0.10% | Q2 2021 | Q3 2023 | 10 |
MRK | MERCK & CO INC NEW | 6 | 3 | 2.17% | 3.02% | 4.93% | Q2 2014 | Q4 2017 | 9 |
AAAP | ADVANCED ACCELERATOR A... | 9 | 9 | 1.66% | 2.16% | 3.06% | Q4 2015 | Q4 2017 | 9 |
JNJ | JOHNSON & JOHNSON | 4 | 1 | 0.29% | 1.58% | 5.66% | Q1 2014 | Q2 2020 | 9 |
LLY | LILLY ELI & CO | 9 | 9 | 1.39% | 1.57% | 1.76% | Q1 2015 | Q1 2017 | 9 |
RXDX | PROMETHEUS BIOSCIENCES... | 9 | 9 | 0.23% | 0.98% | 2.73% | Q1 2021 | Q1 2023 | 9 |
DHR | DANAHER CORP DEL | 5 | 4 | 0.66% | 0.87% | 1.06% | Q3 2014 | Q3 2017 | 9 |
ADPT | ADAPTIVE BIOTECHNOLOGI... | 9 | 9 | 0.52% | 0.70% | 1.05% | Q2 2019 | Q2 2021 | 9 |
AVXS | AVEXIS INC | 9 | 9 | 0.33% | 0.62% | 1.00% | Q1 2016 | Q1 2018 | 9 |
AXGN | AXOGEN INC | 9 | 9 | 0.32% | 0.60% | 1.05% | Q2 2017 | Q2 2019 | 9 |
WARBY PARKER INC | 9 | 9 | 0.33% | 0.54% | 0.88% | Q3 2021 | Q3 2023 | 9 | |
CYTOKINETICS INC | 9 | 9 | 0.33% | 0.52% | 0.82% | Q1 2020 | Q1 2022 | 9 | |
ZBH | ZIMMER BIOMET HLDGS INC | 9 | 9 | 0.11% | 0.47% | 1.07% | Q4 2016 | Q4 2018 | 9 |
ALKS | ALKERMES PLC | 6 | 3 | 0.15% | 0.43% | 0.62% | Q4 2013 | Q2 2017 | 9 |
SAGE | SAGE THERAPEUTICS INC | 9 | 9 | 0.09% | 0.36% | 0.61% | Q3 2017 | Q3 2019 | 9 |
OTIC | OTONOMY INC | 9 | 9 | 0.15% | 0.31% | 0.54% | Q2 2015 | Q2 2017 | 9 |
XNPT | XENOPORT INC | 8 | 1 | 0.12% | 0.30% | 0.62% | Q4 2013 | Q2 2016 | 9 |
EGALET CORP | 9 | 9 | 0.11% | 0.28% | 0.45% | Q2 2016 | Q2 2018 | 9 | |
NVLS | NIVALIS THERAPEUTICS INC | 9 | 9 | 0.07% | 0.25% | 0.62% | Q2 2015 | Q2 2017 | 9 |
FUSN | FUSION PHARMACEUTICALS... | 9 | 9 | 0.06% | 0.20% | 0.45% | Q2 2020 | Q2 2022 | 9 |
ICOSAVAX INC | 9 | 9 | 0.06% | 0.20% | 0.46% | Q3 2021 | Q3 2023 | 9 | |
EGLTQ | EGALET CORP | 9 | 9 | 0.02% | 0.14% | 0.32% | Q3 2015 | Q3 2017 | 9 |
ANTH | ANTHERA PHARMACEUTICAL... | 9 | 9 | 0.02% | 0.13% | 0.30% | Q1 2015 | Q1 2017 | 9 |
IMRA | IMARA INC | 5 | 4 | 0.03% | 0.13% | 0.30% | Q1 2020 | Q3 2022 | 9 |
FULC | FULCRUM THERAPEUTICS INC | 9 | 9 | 0.05% | 0.12% | 0.27% | Q3 2021 | Q3 2023 | 9 |
ACRX | ACELRX PHARMACEUTICALS... | 9 | 9 | 0.03% | 0.09% | 0.14% | Q3 2020 | Q3 2022 | 9 |
VINC | VINCERX PHARMA INC | 9 | 9 | 0.02% | 0.08% | 0.27% | Q3 2021 | Q3 2023 | 9 |
WRIGHT MED GROUP INC | 9 | 9 | 0.04% | 0.06% | 0.08% | Q1 2016 | Q1 2018 | 9 | |
THOR | THORATEC CORP | 8 | 8 | 0.62% | 2.32% | 3.60% | Q4 2013 | Q3 2015 | 8 |
PFE | PFIZER INC | 7 | 1 | 0.01% | 2.03% | 2.75% | Q1 2015 | Q4 2019 | 8 |
CVS | CVS HEALTH CORP | 8 | 8 | 0.94% | 1.51% | 1.95% | Q4 2013 | Q3 2015 | 8 |
TMH | TEAM HEALTH HOLDINGS INC | 8 | 8 | 1.09% | 1.50% | 1.91% | Q4 2013 | Q3 2015 | 8 |
LOXO | LOXO ONCOLOGY INC | 8 | 8 | 0.44% | 1.29% | 1.94% | Q1 2017 | Q4 2018 | 8 |
SYK | STRYKER CORP | 8 | 8 | 0.89% | 1.25% | 1.54% | Q4 2017 | Q3 2019 | 8 |
DVA | DAVITA INC | 5 | 3 | 0.26% | 0.77% | 1.15% | Q1 2015 | Q4 2018 | 8 |
HOLX | HOLOGIC INC | 5 | 3 | 0.59% | 0.70% | 0.96% | Q2 2016 | Q2 2018 | 8 |
HRC | HILL ROM HLDGS INC | 5 | 3 | 0.18% | 0.68% | 1.45% | Q2 2014 | Q2 2017 | 8 |
VERV | VERVE THERAPEUTICS INC | 8 | 8 | 0.19% | 0.54% | 1.15% | Q2 2021 | Q1 2023 | 8 |
WX | WUXI PHARMATECH CAYMAN... | 8 | 8 | 0.42% | 0.52% | 0.61% | Q4 2013 | Q3 2015 | 8 |
RLYP | RELYPSA INC | 7 | 1 | 0.10% | 0.50% | 0.69% | Q2 2014 | Q2 2016 | 8 |
CMPX | COMPASS THERAPEUTICS INC | 8 | 8 | 0.18% | 0.39% | 0.64% | Q4 2021 | Q3 2023 | 8 |
AURA BIOSCIENCES INC | 8 | 8 | 0.17% | 0.35% | 0.56% | Q4 2021 | Q3 2023 | 8 | |
CYTK | CYTOKINETICS INC | 6 | 2 | 0.05% | 0.31% | 0.55% | Q2 2020 | Q3 2023 | 8 |
PRLD | PRELUDE THERAPEUTICS INC | 8 | 8 | 0.06% | 0.23% | 0.55% | Q3 2020 | Q2 2022 | 8 |
GNCA | GENOCEA BIOSCIENCES INC | 8 | 8 | 0.13% | 0.20% | 0.36% | Q3 2015 | Q2 2017 | 8 |
NGM | NGM BIOPHARMACEUTICALS... | 8 | 8 | 0.15% | 0.20% | 0.23% | Q2 2019 | Q1 2021 | 8 |
XILIO THERAPEUTICS INC | 8 | 8 | 0.08% | 0.15% | 0.44% | Q4 2021 | Q3 2023 | 8 | |
GRTX | GALERA THERAPEUTICS INC | 8 | 8 | 0.10% | 0.14% | 0.21% | Q4 2019 | Q3 2021 | 8 |
DMTX | DIMENSION THERAPEUTICS... | 8 | 8 | 0.02% | 0.11% | 0.23% | Q4 2015 | Q3 2017 | 8 |
THESEUS PHARMACEUTICAL... | 8 | 8 | 0.03% | 0.08% | 0.13% | Q4 2021 | Q3 2023 | 8 | |
BLSA | BCLS ACQUISITION CORP | 8 | 8 | 0.06% | 0.07% | 0.09% | Q4 2020 | Q3 2022 | 8 |
JYAC | JIYA ACQUISITION CORP | 8 | 8 | 0.04% | 0.05% | 0.06% | Q4 2020 | Q3 2022 | 8 |
ILMN | ILLUMINA INC | 7 | 7 | 0.28% | 1.04% | 2.18% | Q4 2013 | Q2 2015 | 7 |
MD | MEDNAX INC | 5 | 2 | 0.21% | 0.74% | 1.06% | Q4 2013 | Q3 2016 | 7 |
SRRA | SIERRA ONCOLOGY INC | 7 | 7 | 0.19% | 0.71% | 1.88% | Q4 2020 | Q2 2022 | 7 |
ANTM | ANTHEM INC | 4 | 3 | 0.20% | 0.71% | 1.41% | Q2 2015 | Q3 2019 | 7 |
AMYLYX PHARMACEUTICALS... | 7 | 7 | 0.29% | 0.69% | 1.09% | Q1 2022 | Q3 2023 | 7 | |
KIN | KINDRED BIOSCIENCES INC | 7 | 7 | 0.12% | 0.33% | 0.83% | Q1 2014 | Q3 2015 | 7 |
GTHX | G1 THERAPEUTICS INC | 7 | 7 | 0.09% | 0.32% | 0.50% | Q2 2017 | Q4 2018 | 7 |
CLDX | CELLDEX THERAPEUTICS I... | 7 | 7 | 0.08% | 0.31% | 0.45% | Q1 2022 | Q3 2023 | 7 |
AMYT | AMRYT PHARMA PLC | 7 | 7 | 0.23% | 0.30% | 0.46% | Q3 2021 | Q1 2023 | 7 |
ATHA | ATHIRA PHARMA INC | 7 | 7 | 0.11% | 0.30% | 0.62% | Q3 2020 | Q1 2022 | 7 |
KURA | KURA ONCOLOGY INC | 4 | 3 | 0.02% | 0.29% | 0.44% | Q1 2018 | Q3 2021 | 7 |
STE | STERIS PLC | 7 | 7 | 0.18% | 0.26% | 0.30% | Q2 2016 | Q4 2017 | 7 |
CNST | CONSTELLATION PHARMCET... | 7 | 7 | 0.12% | 0.25% | 0.42% | Q4 2019 | Q2 2021 | 7 |
NBRV | NABRIVA THERAPEUTICS AG | 7 | 7 | 0.17% | 0.24% | 0.36% | Q3 2015 | Q1 2017 | 7 |
OHPAU | ORION ACQUISITION CORP | 7 | 7 | 0.20% | 0.23% | 0.28% | Q1 2021 | Q3 2022 | 7 |
CMTA | CLEMENTIA PHARMACEUTIC... | 7 | 7 | 0.14% | 0.22% | 0.30% | Q3 2017 | Q1 2019 | 7 |
TRILLIUM THERAPEUTICS INC | 7 | 7 | 0.12% | 0.18% | 0.28% | Q1 2020 | Q3 2021 | 7 | |
LJPC | LA JOLLA PHARMACEUTICA... | 7 | 7 | 0.07% | 0.17% | 0.28% | Q1 2018 | Q3 2019 | 7 |
LPTX | LEAP THERAPEUTICS INC | 7 | 7 | 0.04% | 0.14% | 0.30% | Q3 2021 | Q1 2023 | 7 |
TORC | RESTORBIO INC | 7 | 7 | 0.10% | 0.14% | 0.22% | Q1 2018 | Q3 2019 | 7 |
FSTX | F-STAR THERAPEUTICS INC | 7 | 7 | 0.07% | 0.12% | 0.18% | Q2 2021 | Q4 2022 | 7 |
VIGIL NEUROSCIENCE INC | 7 | 7 | 0.04% | 0.09% | 0.14% | Q1 2022 | Q3 2023 | 7 | |
PSTX | POSEIDA THERAPEUTICS INC | 7 | 7 | 0.03% | 0.06% | 0.08% | Q3 2020 | Q1 2022 | 7 |
DERMIRA INC | 7 | 7 | 0.03% | 0.03% | 0.04% | Q2 2018 | Q4 2019 | 7 | |
B108PS | ACTAVIS PLC | 6 | 6 | 1.47% | 2.64% | 3.28% | Q4 2013 | Q1 2015 | 6 |
FLML | FLAMEL TECHNOLOGIES SA | 6 | 6 | 0.12% | 1.38% | 2.32% | Q1 2014 | Q2 2015 | 6 |
CNC | CENTENE CORP DEL | 6 | 6 | 0.40% | 1.31% | 2.29% | Q3 2019 | Q4 2020 | 6 |
PCYC | PHARMACYCLICS INC | 6 | 6 | 0.70% | 1.20% | 2.11% | Q4 2013 | Q1 2015 | 6 |
CI | CIGNA CORP NEW | 6 | 6 | 0.48% | 0.88% | 1.31% | Q1 2019 | Q2 2020 | 6 |
INOV | INOVALON HLDGS INC | 6 | 6 | 0.14% | 0.80% | 1.16% | Q1 2015 | Q2 2016 | 6 |
WLTW | WILLIS TOWERS WATSON P... | 6 | 6 | 0.49% | 0.78% | 0.90% | Q3 2016 | Q4 2017 | 6 |
WBA | WALGREENS BOOTS ALLIAN... | 6 | 6 | 0.34% | 0.78% | 0.99% | Q1 2016 | Q2 2017 | 6 |
INSP | INSPIRE MED SYS INC | 5 | 1 | 0.24% | 0.57% | 0.85% | Q1 2020 | Q3 2023 | 6 |
QURE | UNIQURE NV | 6 | 6 | 0.16% | 0.51% | 0.91% | Q3 2019 | Q4 2020 | 6 |
IMTX | IMMATICS N.V | 6 | 6 | 0.29% | 0.48% | 0.70% | Q2 2022 | Q3 2023 | 6 |
BRKS | AZENTA INC | 6 | 6 | 0.34% | 0.47% | 0.64% | Q2 2022 | Q3 2023 | 6 |
INSYQ | INSYS THERAPEUTICS INC... | 6 | 6 | 0.07% | 0.46% | 0.73% | Q2 2015 | Q3 2016 | 6 |
PPD | PPD INC | 6 | 6 | 0.33% | 0.46% | 0.62% | Q1 2020 | Q2 2021 | 6 |
AXNX | AXONICS MODULATION TEC... | 6 | 6 | 0.13% | 0.43% | 0.96% | Q4 2018 | Q1 2020 | 6 |
GI | ENDOCHOICE HLDGS INC | 6 | 6 | 0.26% | 0.41% | 0.69% | Q2 2015 | Q3 2016 | 6 |
CERN | CERNER CORP | 2 | 2 | 0.08% | 0.36% | 0.68% | Q4 2013 | Q3 2016 | 6 |
ETRM | ENTEROMEDICS INC | 6 | 6 | 0.07% | 0.21% | 0.27% | Q4 2013 | Q1 2015 | 6 |
STTK | SHATTUCK LABS INC | 6 | 6 | 0.03% | 0.20% | 0.54% | Q4 2020 | Q1 2022 | 6 |
NRIX | NURIX THERAPEUTICS INC | 6 | 6 | 0.16% | 0.20% | 0.23% | Q3 2020 | Q4 2021 | 6 |
TXG | 10X GENOMICS INC | 6 | 6 | 0.13% | 0.19% | 0.24% | Q3 2019 | Q4 2020 | 6 |
ALDER BIOPHARMACEUTICA... | 6 | 6 | 0.17% | 0.19% | 0.20% | Q1 2018 | Q2 2019 | 6 | |
CORV | CORREVIO PHARMA CORP | 6 | 6 | 0.09% | 0.14% | 0.18% | Q2 2018 | Q3 2019 | 6 |
BEAM | BEAM THERAPEUTICS INC | 6 | 6 | 0.07% | 0.10% | 0.14% | Q2 2022 | Q3 2023 | 6 |
OREXQ | OREXIGEN THERAPEUTICS INC | 6 | 6 | 0.01% | 0.02% | 0.03% | Q3 2016 | Q4 2017 | 6 |
SHPG | SHIRE PLC | 4 | 1 | 0.24% | 1.29% | 1.64% | Q2 2016 | Q1 2018 | 5 |
TRNX | TORNIER N V | 4 | 1 | 0.87% | 1.18% | 1.62% | Q4 2013 | Q3 2015 | 5 |
AVNR | AVANIR PHARMACEUTICALS... | 5 | 5 | 0.25% | 1.11% | 2.18% | Q4 2013 | Q4 2014 | 5 |
SRCL | STERICYCLE INC | 5 | 5 | 0.77% | 0.85% | 0.96% | Q1 2014 | Q1 2015 | 5 |
INGN | INOGEN INC | 5 | 5 | 0.43% | 0.73% | 1.11% | Q4 2017 | Q4 2018 | 5 |
RCPT | RECEPTOS INC | 4 | 1 | 0.22% | 0.72% | 1.00% | Q1 2014 | Q2 2015 | 5 |
ZSPH | ZS PHARMA INC | 5 | 5 | 0.52% | 0.63% | 0.83% | Q3 2014 | Q3 2015 | 5 |
CBST | CUBIST PHARMACEUTICALS... | 5 | 5 | 0.43% | 0.59% | 1.03% | Q4 2013 | Q4 2014 | 5 |
IMVT | IMMUNOVANT INC | 4 | 1 | 0.16% | 0.53% | 0.87% | Q1 2020 | Q3 2023 | 5 |
ARNA | ARENA PHARMACEUTICALS INC | 5 | 5 | 0.25% | 0.49% | 0.63% | Q3 2017 | Q3 2018 | 5 |
CGEM | CULLINAN ONCOLOGY INC | 5 | 5 | 0.17% | 0.49% | 0.98% | Q1 2021 | Q1 2022 | 5 |
OSH | OAK STR HEALTH INC | 5 | 5 | 0.39% | 0.43% | 0.49% | Q3 2020 | Q3 2021 | 5 |
CSLT | CASTLIGHT HEALTH INC | 4 | 1 | 0.34% | 0.41% | 0.49% | Q1 2014 | Q3 2015 | 5 |
OSW | ONESPAWORLD HOLDINGS L... | 5 | 5 | 0.15% | 0.26% | 0.48% | Q4 2019 | Q4 2020 | 5 |
INVA | INNOVIVA INC | 5 | 5 | 0.13% | 0.21% | 0.26% | Q2 2016 | Q2 2017 | 5 |
ROKA | ROKA BIOSCIENCE INC | 5 | 5 | 0.04% | 0.14% | 0.39% | Q3 2014 | Q3 2015 | 5 |
GOSS | GOSSAMER BIO INC | 5 | 5 | 0.02% | 0.13% | 0.49% | Q3 2022 | Q3 2023 | 5 |
SLDB | SOLID BIOSCIENCES INC | 5 | 5 | 0.02% | 0.09% | 0.16% | Q1 2018 | Q1 2019 | 5 |
MDT | MEDTRONIC PLC | 2 | 2 | 0.89% | 2.48% | 4.18% | Q1 2015 | Q3 2017 | 4 |
TEVA | TEVA PHARMACEUTICAL IN... | 4 | 4 | 1.47% | 1.65% | 1.89% | Q3 2015 | Q2 2016 | 4 |
CAH | CARDINAL HEALTH INC | 4 | 4 | 0.97% | 1.20% | 1.53% | Q4 2013 | Q3 2014 | 4 |
AVIR | ATEA PHARMACEUTICALS INC | 4 | 4 | 0.34% | 1.17% | 2.28% | Q4 2020 | Q3 2021 | 4 |
ABC | AMERISOURCEBERGEN CORP | 2 | 1 | 0.56% | 0.80% | 1.08% | Q4 2013 | Q2 2018 | 4 |
EAR | EARGO INC | 4 | 4 | 0.14% | 0.77% | 1.14% | Q4 2020 | Q3 2021 | 4 |
AFAM | ALMOST FAMILY INC | 4 | 4 | 0.37% | 0.76% | 1.13% | Q1 2017 | Q4 2017 | 4 |
THRX | THERAVANCE INC | 4 | 4 | 0.50% | 0.71% | 0.96% | Q4 2013 | Q3 2014 | 4 |
GRPH | GRAPHITE BIO INC | 4 | 4 | 0.23% | 0.71% | 1.31% | Q2 2021 | Q1 2022 | 4 |
CVD | COVANCE INC | 4 | 4 | 0.56% | 0.70% | 0.80% | Q4 2013 | Q3 2014 | 4 |
FEIC | FEI CO | 4 | 4 | 0.55% | 0.68% | 0.78% | Q4 2013 | Q3 2014 | 4 |
APRE | APREA THERAPEUTICS INC | 4 | 4 | 0.32% | 0.66% | 1.05% | Q4 2019 | Q3 2020 | 4 |
CINCOR PHARMA INC | 4 | 4 | 0.33% | 0.59% | 1.02% | Q1 2022 | Q4 2022 | 4 | |
DCPH | DECIPHERA PHARMACEUTIC... | 4 | 4 | 0.34% | 0.52% | 0.83% | Q3 2019 | Q2 2020 | 4 |
CNXR | CONNECTURE INC | 4 | 4 | 0.14% | 0.45% | 0.58% | Q4 2014 | Q3 2015 | 4 |
ADXS | ADVAXIS INC | 4 | 4 | 0.21% | 0.44% | 0.66% | Q4 2014 | Q3 2015 | 4 |
RPRX | ROYALTY PHARMA PLC | 4 | 4 | 0.08% | 0.44% | 0.67% | Q2 2020 | Q1 2021 | 4 |
TGTX | TG THERAPEUTICS INC | 4 | 4 | 0.28% | 0.41% | 0.54% | Q2 2020 | Q1 2021 | 4 |
RCKT | ROCKET PHARMACEUTICALS... | 4 | 4 | 0.25% | 0.37% | 0.47% | Q4 2020 | Q3 2021 | 4 |
OPHT | OPHTHOTECH CORP | 3 | 1 | 0.18% | 0.34% | 0.54% | Q4 2013 | Q3 2016 | 4 |
MYOK | MYOKARDIA INC | 3 | 1 | 0.08% | 0.31% | 0.46% | Q3 2017 | Q2 2020 | 4 |
DISC MEDICINE INC | 4 | 4 | 0.16% | 0.29% | 0.46% | Q4 2022 | Q3 2023 | 4 | |
TARA | PROTARA THERAPEUTICS INC | 4 | 4 | 0.13% | 0.24% | 0.33% | Q3 2020 | Q2 2021 | 4 |
BIOHAVEN LTD | 4 | 4 | 0.03% | 0.18% | 0.23% | Q3 2022 | Q2 2023 | 4 | |
ALT | ALTIMMUNE INC | 4 | 4 | 0.02% | 0.05% | 0.09% | Q3 2022 | Q2 2023 | 4 |
EUCRU | EUCRATES BIOMEDICAL AC... | 4 | 4 | 0.04% | 0.04% | 0.05% | Q4 2020 | Q3 2021 | 4 |
TMPMU | TURMERIC ACQUISITION CORP | 4 | 4 | 0.04% | 0.04% | 0.04% | Q4 2020 | Q3 2021 | 4 |
PHICU | POPULATION HEALTH INVS... | 4 | 4 | 0.04% | 0.04% | 0.04% | Q4 2020 | Q3 2021 | 4 |
HLXA | HELIX ACQUISITION CORP | 4 | 4 | 0.03% | 0.03% | 0.04% | Q4 2020 | Q3 2021 | 4 |
BMYRT | BRISTOL-MYERS SQUIBB CO | 4 | 4 | 0.01% | 0.02% | 0.03% | Q4 2019 | Q3 2020 | 4 |
ACELRX PHARMACEUTICALS... | 4 | 4 | 0.01% | 0.01% | 0.02% | Q4 2022 | Q3 2023 | 4 | |
MDT | MEDTRONIC INC | 3 | 3 | 4.64% | 4.81% | 5.06% | Q2 2014 | Q4 2014 | 3 |
ITMN | INTERMUNE INC | 3 | 3 | 0.66% | 2.69% | 4.26% | Q4 2013 | Q2 2014 | 3 |
STJ | ST JUDE MED INC | 1 | 1 | 1.24% | 2.17% | 2.71% | Q2 2014 | Q3 2015 | 3 |
WAG | WALGREEN CO | 3 | 3 | 1.06% | 1.15% | 1.31% | Q4 2013 | Q2 2014 | 3 |
FRX | FOREST LABS INC | 3 | 3 | 0.73% | 0.95% | 1.15% | Q4 2013 | Q2 2014 | 3 |
MWIV | MWI VETERINARY SUPPLY INC | 3 | 3 | 0.78% | 0.88% | 0.96% | Q2 2014 | Q4 2014 | 3 |
RAD | RITE AID CORP | 3 | 3 | 0.68% | 0.84% | 1.03% | Q2 2014 | Q4 2014 | 3 |
BIIB | BIOGEN INC | 2 | 1 | 0.68% | 0.80% | 0.89% | Q1 2019 | Q4 2020 | 3 |
ANAC | ANACOR PHARMACEUTICALS... | 3 | 3 | 0.66% | 0.76% | 0.82% | Q3 2015 | Q1 2016 | 3 |
PTHN | PATHEON N V | 3 | 3 | 0.61% | 0.71% | 0.77% | Q3 2016 | Q1 2017 | 3 |
BOLT | BOLT BIOTHERAPEUTICS INC | 3 | 3 | 0.44% | 0.68% | 1.12% | Q1 2021 | Q3 2021 | 3 |
CYBX | CYBERONICS INC | 3 | 3 | 0.44% | 0.56% | 0.72% | Q2 2014 | Q4 2014 | 3 |
ABCO | ADVISORY BRD CO | 3 | 3 | 0.46% | 0.56% | 0.67% | Q4 2013 | Q2 2014 | 3 |
AGN | ALLERGAN INC | 3 | 3 | 0.46% | 0.53% | 0.63% | Q2 2014 | Q4 2014 | 3 |
BFAM | BRIGHT HORIZONS FAM SO... | 3 | 3 | 0.32% | 0.52% | 0.64% | Q2 2020 | Q4 2020 | 3 |
RVMD | REVOLUTION MEDICINES INC | 3 | 3 | 0.36% | 0.45% | 0.54% | Q1 2023 | Q3 2023 | 3 |
EVHC | ENVISION HEALTHCARE CORP | 2 | 1 | 0.19% | 0.44% | 0.61% | Q4 2016 | Q2 2018 | 3 |
AERI | AERIE PHARMACEUTICALS INC | 3 | 3 | 0.32% | 0.41% | 0.48% | Q3 2014 | Q1 2015 | 3 |
MINERALYS THERAPEUTICS... | 3 | 3 | 0.30% | 0.40% | 0.47% | Q1 2023 | Q3 2023 | 3 | |
LGND | LIGAND PHARMACEUTICALS... | 3 | 3 | 0.30% | 0.40% | 0.48% | Q3 2016 | Q1 2017 | 3 |
ECYT | ENDOCYTE INC | 3 | 3 | 0.26% | 0.39% | 0.55% | Q1 2018 | Q3 2018 | 3 |
ABOS | ACUMEN PHARMACEUTICALS... | 2 | 1 | 0.25% | 0.35% | 0.49% | Q3 2021 | Q3 2023 | 3 |
IFRX | INFLARX NV | 3 | 3 | 0.22% | 0.31% | 0.37% | Q3 2018 | Q1 2019 | 3 |
NEURODERM LTD | 3 | 3 | 0.13% | 0.30% | 0.43% | Q1 2017 | Q3 2017 | 3 | |
APTX | APTINYX INC | 3 | 3 | 0.24% | 0.29% | 0.32% | Q2 2018 | Q4 2018 | 3 |
ARWR | ARROWHEAD RESH CORP | 3 | 3 | 0.26% | 0.28% | 0.30% | Q1 2014 | Q3 2014 | 3 |
PLRX | PLIANT THERAPEUTICS INC | 3 | 3 | 0.21% | 0.25% | 0.31% | Q1 2023 | Q3 2023 | 3 |
MNLO | MENLO THERAPEUTICS INC | 3 | 3 | 0.10% | 0.25% | 0.53% | Q1 2018 | Q3 2018 | 3 |
DYAX | DYAX CORP | 3 | 3 | 0.18% | 0.24% | 0.35% | Q2 2015 | Q4 2015 | 3 |
INNV | INNOVAGE HLDG CORP | 3 | 3 | 0.07% | 0.24% | 0.38% | Q1 2021 | Q3 2021 | 3 |
PETX | ARATANA THERAPEUTICS INC | 3 | 3 | 0.02% | 0.23% | 0.33% | Q2 2015 | Q4 2015 | 3 |
RPTP | RAPTOR PHARMACEUTICAL ... | 3 | 3 | 0.15% | 0.22% | 0.35% | Q1 2015 | Q3 2015 | 3 |
ADVM | ADVERUM BIOTECHNOLOGIE... | 3 | 3 | 0.18% | 0.20% | 0.22% | Q1 2018 | Q3 2018 | 3 |
DAWN | DAY ONE BIOPHARMACEUTI... | 3 | 3 | 0.15% | 0.17% | 0.19% | Q2 2021 | Q4 2021 | 3 |
PTCT | PTC THERAPEUTICS INC | 3 | 3 | 0.09% | 0.16% | 0.23% | Q1 2015 | Q3 2015 | 3 |
PASG | PASSAGE BIO INC | 3 | 3 | 0.07% | 0.12% | 0.15% | Q1 2020 | Q3 2020 | 3 |
EQRX INC | 3 | 3 | 0.10% | 0.12% | 0.14% | Q1 2022 | Q3 2022 | 3 | |
PRTA | PROTHENA CORP PLC | 3 | 3 | 0.04% | 0.10% | 0.21% | Q4 2017 | Q2 2018 | 3 |
SPHS | SOPHIRIS BIO INC | 3 | 3 | 0.08% | 0.08% | 0.09% | Q4 2015 | Q2 2016 | 3 |
NUVB | NUVATION BIO INC | 3 | 3 | 0.04% | 0.06% | 0.09% | Q1 2021 | Q3 2021 | 3 |
MIRN | MIRNA THERAPEUTICS INC | 3 | 3 | 0.05% | 0.06% | 0.07% | Q4 2015 | Q2 2016 | 3 |
NLNK | NEWLINK GENETICS CORP | 3 | 3 | 0.03% | 0.05% | 0.09% | Q1 2017 | Q3 2017 | 3 |
FSII | FS DEVELOPMENT CORP II | 3 | 3 | 0.04% | 0.04% | 0.04% | Q1 2021 | Q3 2021 | 3 |
KLDO | KALEIDO BIOSCIENCES INC | 3 | 3 | 0.03% | 0.04% | 0.06% | Q1 2019 | Q3 2019 | 3 |
BXLT | BAXALTA INC | 2 | 2 | 2.40% | 2.57% | 2.74% | Q4 2015 | Q1 2016 | 2 |
FTSV | FORTY SEVEN INC | 2 | 2 | 0.56% | 1.16% | 1.76% | Q4 2019 | Q1 2020 | 2 |
ADPTQ | ADEPTUS HEALTH INC | 2 | 2 | 1.04% | 1.10% | 1.17% | Q2 2015 | Q3 2015 | 2 |
BCR | BARD C R INC | 2 | 2 | 0.85% | 0.88% | 0.92% | Q2 2017 | Q3 2017 | 2 |
UHS | UNIVERSAL HLTH SVCS INC | 2 | 2 | 0.83% | 0.84% | 0.85% | Q4 2013 | Q1 2014 | 2 |
NUVA | NUVASIVE INC | 2 | 2 | 0.68% | 0.71% | 0.75% | Q1 2018 | Q2 2018 | 2 |
CRL | CHARLES RIV LABS INTL INC | 2 | 2 | 0.68% | 0.69% | 0.69% | Q1 2014 | Q2 2014 | 2 |
KYTH | KYTHERA BIOPHARMACEUTI... | 2 | 2 | 0.54% | 0.65% | 0.77% | Q1 2015 | Q2 2015 | 2 |
CTLT | CATALENT INC | 2 | 2 | 0.44% | 0.61% | 0.78% | Q3 2014 | Q4 2014 | 2 |
STE | STERIS CORP | 2 | 2 | 0.58% | 0.60% | 0.61% | Q4 2014 | Q1 2015 | 2 |
MYL | MYLAN INC | 2 | 2 | 0.57% | 0.58% | 0.60% | Q4 2013 | Q1 2014 | 2 |
BHG | BRIGHT HEALTH GROUP INC | 2 | 2 | 0.30% | 0.55% | 0.80% | Q2 2021 | Q3 2021 | 2 |
IMMUNEERING CORP | 2 | 2 | 0.41% | 0.51% | 0.61% | Q3 2021 | Q4 2021 | 2 | |
VSAR | VERSARTIS INC | 2 | 2 | 0.36% | 0.50% | 0.62% | Q2 2014 | Q3 2014 | 2 |
AADI BIOSCIENCES INC | 2 | 2 | 0.30% | 0.39% | 0.47% | Q3 2021 | Q4 2021 | 2 | |
ALLO | ALLOGENE THERAPEUTICS INC | 2 | 2 | 0.20% | 0.36% | 0.52% | Q1 2020 | Q2 2020 | 2 |
PFNX | PFENEX INC | 2 | 2 | 0.28% | 0.33% | 0.37% | Q3 2014 | Q4 2014 | 2 |
MEDP | MEDPACE HLDGS INC | 2 | 2 | 0.25% | 0.29% | 0.33% | Q3 2016 | Q4 2016 | 2 |
EARS | AURIS MED HLDG AG | 2 | 2 | 0.24% | 0.25% | 0.26% | Q1 2016 | Q2 2016 | 2 |
TRIV | TRIVASCULAR TECHNOLOGI... | 2 | 2 | 0.19% | 0.24% | 0.29% | Q4 2014 | Q1 2015 | 2 |
GTXI | GTX INC DEL | 2 | 2 | 0.21% | 0.24% | 0.27% | Q1 2018 | Q2 2018 | 2 |
PTLA | PORTOLA PHARMACEUTICAL... | 1 | 1 | 0.06% | 0.23% | 0.40% | Q1 2016 | Q2 2017 | 2 |
BIOD | BIODEL INC | 2 | 2 | 0.14% | 0.22% | 0.30% | Q2 2015 | Q3 2015 | 2 |
STAA | STAAR SURGICAL CO | 2 | 2 | 0.21% | 0.21% | 0.22% | Q1 2020 | Q2 2020 | 2 |
KRYS | KRYSTAL BIOTECH INC | 2 | 2 | 0.10% | 0.19% | 0.28% | Q2 2023 | Q3 2023 | 2 |
IMGN | IMMUNOGEN INC | 2 | 2 | 0.05% | 0.19% | 0.32% | Q2 2023 | Q3 2023 | 2 |
GKOS | GLAUKOS CORP | 2 | 2 | 0.13% | 0.16% | 0.18% | Q1 2017 | Q2 2017 | 2 |
AAVL | AVALANCHE BIOTECHNOLOG... | 1 | 1 | 0.04% | 0.15% | 0.27% | Q3 2014 | Q1 2015 | 2 |
IRWD | IRONWOOD PHARMACEUTICA... | 2 | 2 | 0.15% | 0.15% | 0.15% | Q3 2017 | Q4 2017 | 2 |
ITOS | ITEOS THERAPEUTICS INC | 2 | 2 | 0.12% | 0.13% | 0.14% | Q3 2020 | Q4 2020 | 2 |
PANAU | PANACEA ACQUISITION CORP | 2 | 2 | 0.11% | 0.12% | 0.12% | Q3 2020 | Q4 2020 | 2 |
ARIA | ARIAD PHARMACEUTICALS INC | 2 | 2 | 0.02% | 0.11% | 0.21% | Q3 2016 | Q4 2016 | 2 |
IGMS | IGM BIOSCIENCES INC | 2 | 2 | 0.04% | 0.11% | 0.19% | Q2 2020 | Q3 2020 | 2 |
ATAI | ATAI LIFE SCIENCES NV | 2 | 2 | 0.10% | 0.11% | 0.12% | Q2 2021 | Q3 2021 | 2 |
ANNX | ANNEXON INC | 2 | 2 | 0.02% | 0.10% | 0.18% | Q3 2020 | Q4 2020 | 2 |
ALPN | ALPINE IMMUNE SCIENCES... | 2 | 2 | 0.08% | 0.08% | 0.08% | Q3 2017 | Q4 2017 | 2 |
LEAP THERAPEUTICS INC | 2 | 2 | 0.04% | 0.06% | 0.08% | Q2 2023 | Q3 2023 | 2 | |
ACELYRIN INC | 2 | 2 | 0.04% | 0.06% | 0.07% | Q2 2023 | Q3 2023 | 2 | |
LSAQ | LIFESCI ACQUISITION II... | 2 | 2 | 0.05% | 0.05% | 0.05% | Q4 2020 | Q1 2021 | 2 |
ANTH | ANTHERA PHARMACEUTICAL... | 2 | 2 | 0.01% | 0.01% | 0.01% | Q2 2017 | Q3 2017 | 2 |
DARE | DARE BIOSCIENCE INC | 2 | 2 | 0.01% | 0.01% | 0.01% | Q3 2017 | Q4 2017 | 2 |
F113PS | COVIDIEN PLC | 1 | 1 | 3.53% | 3.53% | 3.53% | Q4 2014 | Q4 2014 | 1 |
GENTY | GENTIUM S P A | 1 | 1 | 2.44% | 2.44% | 2.44% | Q4 2013 | Q4 2013 | 1 |
SLXP | SALIX PHARMACEUTICALS INC | 1 | 1 | 1.04% | 1.04% | 1.04% | Q4 2014 | Q4 2014 | 1 |
AEGR | AEGERION PHARMACEUTICA... | 1 | 1 | 1.00% | 1.00% | 1.00% | Q4 2013 | Q4 2013 | 1 |
LH | LABORATORY CORP AMER H... | 1 | 1 | 0.88% | 0.88% | 0.88% | Q1 2015 | Q1 2015 | 1 |
AUXL | AUXILIUM PHARMACEUTICA... | 1 | 1 | 0.74% | 0.74% | 0.74% | Q4 2013 | Q4 2013 | 1 |
AZN | ASTRAZENECA PLC | 1 | 1 | 0.70% | 0.70% | 0.70% | Q1 2021 | Q1 2021 | 1 |
DRNA | DICERNA PHARMACEUTICAL... | 1 | 1 | 0.68% | 0.68% | 0.68% | Q1 2014 | Q1 2014 | 1 |
TPTX | TURNING POINT THERAPEU... | 1 | 1 | 0.60% | 0.60% | 0.60% | Q2 2022 | Q2 2022 | 1 |
CFN | CAREFUSION CORP | 1 | 1 | 0.54% | 0.54% | 0.54% | Q2 2014 | Q2 2014 | 1 |
ARA | AMERICAN RENAL ASSOCIA... | 1 | 1 | 0.54% | 0.54% | 0.54% | Q2 2016 | Q2 2016 | 1 |
CORSICANTO LTD | 1 | 1 | 0.53% | 0.53% | 0.53% | Q2 2016 | Q2 2016 | 1 | |
ACTPRA | ACTAVIS PLC | 1 | 1 | 0.48% | 0.48% | 0.48% | Q1 2015 | Q1 2015 | 1 |
ELAN | ELANCO ANIMAL HEALTH INC | 1 | 1 | 0.47% | 0.47% | 0.47% | Q3 2018 | Q3 2018 | 1 |
ABT | ABBOTT LABS | 1 | 1 | 0.41% | 0.41% | 0.41% | Q3 2019 | Q3 2019 | 1 |
ZTS | ZOETIS INC | 1 | 1 | 0.36% | 0.36% | 0.36% | Q1 2018 | Q1 2018 | 1 |
AIRM | AIR METHODS CORP | 1 | 1 | 0.35% | 0.35% | 0.35% | Q4 2013 | Q4 2013 | 1 |
LXRX | LEXICON PHARMACEUTICAL... | 1 | 1 | 0.33% | 0.33% | 0.33% | Q2 2017 | Q2 2017 | 1 |
CADX | CADENCE PHARMACEUTICAL... | 1 | 1 | 0.29% | 0.29% | 0.29% | Q4 2013 | Q4 2013 | 1 |
ENTA | ENANTA PHARMACEUTICALS... | 1 | 1 | 0.29% | 0.29% | 0.29% | Q3 2018 | Q3 2018 | 1 |
ABLX | ABLYNX NV | 1 | 1 | 0.28% | 0.28% | 0.28% | Q4 2017 | Q4 2017 | 1 |
BIOS | BIOSCRIP INC | 1 | 1 | 0.27% | 0.27% | 0.27% | Q3 2016 | Q3 2016 | 1 |
NKTR | NEKTAR THERAPEUTICS | 1 | 1 | 0.26% | 0.26% | 0.26% | Q4 2013 | Q4 2013 | 1 |
BNFT | BENEFITFOCUS INC | 1 | 1 | 0.26% | 0.26% | 0.26% | Q1 2015 | Q1 2015 | 1 |
TSRO | TESARO INC | 1 | 1 | 0.25% | 0.25% | 0.25% | Q2 2016 | Q2 2016 | 1 |
CLLS | CELLECTIS S A | 1 | 1 | 0.24% | 0.24% | 0.24% | Q1 2015 | Q1 2015 | 1 |
RPTX | REPARE THERAPEUTICS INC | 1 | 1 | 0.23% | 0.23% | 0.23% | Q2 2020 | Q2 2020 | 1 |
APLS | APELLIS PHARMACEUTICAL... | 1 | 1 | 0.20% | 0.20% | 0.20% | Q2 2021 | Q2 2021 | 1 |
BLU | BELLUS HEALTH INC NEW | 1 | 1 | 0.20% | 0.20% | 0.20% | Q2 2020 | Q2 2020 | 1 |
CNCE | CONCERT PHARMACEUTICAL... | 1 | 1 | 0.18% | 0.18% | 0.18% | Q1 2014 | Q1 2014 | 1 |
SAGIMET BIOSCIENCES INC | 1 | 1 | 0.17% | 0.17% | 0.17% | Q3 2023 | Q3 2023 | 1 | |
CARA | CARA THERAPEUTICS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q1 2017 | Q1 2017 | 1 |
SRPT | SAREPTA THERAPEUTICS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q4 2015 | Q4 2015 | 1 |
ONCE | SPARK THERAPEUTICS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q3 2015 | Q3 2015 | 1 |
BNR | BURNING ROCK BIOTECH LTD | 1 | 1 | 0.15% | 0.15% | 0.15% | Q2 2020 | Q2 2020 | 1 |
AXGT | AXOVANT SCIENCES LTD | 1 | 1 | 0.15% | 0.15% | 0.15% | Q2 2017 | Q2 2017 | 1 |
GDRX | GOODRX HLDGS INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q3 2020 | Q3 2020 | 1 |
AMSG | AMSURG CORP | 1 | 1 | 0.14% | 0.14% | 0.14% | Q3 2016 | Q3 2016 | 1 |
GLYC | GLYCOMIMETICS INC | 1 | 1 | 0.13% | 0.13% | 0.13% | Q2 2017 | Q2 2017 | 1 |
VKTX | VIKING THERAPEUTICS INC | 1 | 1 | 0.13% | 0.13% | 0.13% | Q3 2018 | Q3 2018 | 1 |
CERT | CERTARA INC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q4 2020 | Q4 2020 | 1 |
NARI | INARI MED INC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q2 2020 | Q2 2020 | 1 |
BLCM | BELLICUM PHARMACEUTICA... | 1 | 1 | 0.09% | 0.09% | 0.09% | Q4 2014 | Q4 2014 | 1 |
VICL | VICAL INC | 1 | 1 | 0.09% | 0.09% | 0.09% | Q2 2015 | Q2 2015 | 1 |
IMDZ | IMMUNE DESIGN CORP | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2015 | Q2 2015 | 1 |
BDTX | BLACK DIAMOND THERAPEU... | 1 | 1 | 0.07% | 0.07% | 0.07% | Q2 2023 | Q2 2023 | 1 |
XLRN | ACCELERON PHARMA INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q1 2020 | Q1 2020 | 1 |
KNSA | KINIKSA PHARMACEUTICAL... | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2018 | Q2 2018 | 1 |
ETNB | 89BIO INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q1 2023 | Q1 2023 | 1 |
CNTB | CONNECT BIOPHARMA HLDG... | 1 | 1 | 0.05% | 0.05% | 0.05% | Q1 2021 | Q1 2021 | 1 |
AEGLEA BIOTHERAPEUTICS... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2023 | Q3 2023 | 1 | |
UROV | UROVANT SCIENCES LTD | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2018 | Q3 2018 | 1 |
KALA | KALA PHARMACEUTICALS INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2017 | Q3 2017 | 1 |
APLS | APELLIS PHARMACEUTICAL... | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2021 | Q3 2021 | 1 |
ALT | ALTIMMUNE INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2022 | Q3 2022 | 1 |
CERVOMED INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2023 | Q3 2023 | 1 | |
ARPO | AERPIO PHARMACEUTICALS... | 1 | 1 | 0.00% | 0.00% | 0.00% | Q2 2021 | Q2 2021 | 1 |
GTXI | GTX INC DEL | 1 | 1 | 0.00% | 0.00% | 0.00% | Q3 2018 | Q3 2018 | 1 |
Download |
The securities at the top of the list , including INTUITIVE SURGICAL INC, NEUROCRINE BIOSCIENCES INC, and PACIRA PHARMACEUTICALS INC, are the highest-conviction holdings of Rock Springs Capital Management LP.
The conviction is calculated by counting the number of quarters a security has been reported by Rock Springs Capital Management LP. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Rock Springs Capital Management LP owns currently or has owned in the past.